Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving bortezomib together with gemcitabine hydrochloride may
kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with gemcitabine
hydrochloride works in treating patients with relapsed or refractory Hodgkin's lymphoma.